Hans-Guido Wendel: Featured News

Hans-Guido Wendel: Featured News

Share
Print
Share
Print
Pictured: Hans-Guido Wendel
At Work: Cancer Biologist Hans-Guido Wendel
German-born cancer biologist Hans-Guido Wendel is taking advantage of transformative advances in genomics technology to understand key genetic abnormalities in leukemia and lymphoma.
Hans-Guido Wendel
Tree-Derived Cancer Drug Shows Promise in Treating COVID-19 Virus
Originally explored as a cancer drug, the tree-derived chemical is now being mined for its antiviral properties.
In the Lab
CT scan showing lymphoma in the abdomen between the liver and the gallbladder.
A Metabolic Enzyme Drives Lymphoma and Is a Potential Drug Target
New research from Sloan Kettering Institute investigators pinpoints altered cell metabolism as a cause of B cell lymphoma.
Finding
An illustration of sugar pouring onto NRF2
Sugar Directly Controls a Cancer-Causing Protein, Scientists Find
The discovery suggests a potential new treatment approach for certain cancers.
In the Lab
A scientist looks at illustrations of chromosomes.
When Loss Is a Gain: New Tumor Suppressor Gene Identified in Follicular Lymphoma
The reason certain patients with follicular lymphoma do worse than others may come down to a missing gene.
In the Lab
Illustration of CAR T cells with conveyor belts leading out of them carrying HVEM protein in tablet form.
New Immunotherapy Approach Turns Cells into “Micro-Pharmacies”
A new immunotherapy approach involves engineering CAR T cells to produce proteins that treat lymphoma.
In the Lab
Stained pathology slides of a patient’s tumor (right) and of an organoid made from that tumor (left).
Five Fascinating Approaches to Cancer Science
From tropical plants and 3-D snapshots of worms to tiny particles that light up tumors, here’s a glimpse at some of the fascinating work MSK researchers pursued in 2014 as part of our quest to advance cancer science.
In the Lab
Pictured: Experimental Brain Tumor
Genetic “Kill Switch” Could Make Cell Therapies Safer
Researchers have engineered a gene into therapeutic cells that allows them to turn off tumor growth if some of the cells become cancerous.
In the Lab
An origami crane illustrates the importance of RNA folding for regulating gene translation. The bolded sequences on the crane’s wings indicate the portion that is critical for the manufacture of many cancer-causing proteins.
Compound from Tropical Plant Targets Key Cancer-Causing Genes
Memorial Sloan Kettering researchers have found a naturally occurring compound that can destroy cancer cells in mice by targeting <em>MYC</em>, a cancer-causing gene that has remained elusive until now.
DNA Pioneer Takes Aim at "Cancer Establishments"
Cancer biologists Mark Ptashne, Robert Benezra, and Hans-Guido Wendel commented on the promise and challenges of new treatments for cancer....
Profile
Pictured: Hans-Guido Wendel
Genetic Causes of Blood Cancers Explored
German-born cancer biologist Hans-Guido Wendel is taking advantage of transformative advances in genomics technology to understand key genetic abnormalities in leukemia and lymphoma.
Recipients of the Louis V. Gerstner, Jr. Young Investigators Fund, pictured with Mr. Gerstner. (From left) Iestyn Whitehouse, Hans-Guido Wendel, Mr. Gerstner, Stephen Long, and Timothy Chan.
Memorial Sloan Kettering Names First Gerstner Fund Recipients
Memorial Sloan Kettering has announced the creation of the Louis V. Gerstner, Jr. Young Investigators Fund and has named the fund's first four recipients.